Navigation Links
Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
Date:9/11/2007

., a Johnson & Johnson company, is a global medical device company that develops and markets surgical products for use in general surgery, wound management and women's health & urology. Johnson & Johnson Wound Management, a division of ETHICON, offers a complete portfolio of topical and advanced hemostatic products including SURGICEL* Absorbable Hemostat, SURGIFOAM* Absorbable Gelatin Sponge, EVICEL* Fibrin Sealant (Human), and SURGIFLO* Hemostatic Matrix with FlexTip. For more information about ETHICON, please visit http://www.ethicon.com .

*Trademark


'/>"/>
SOURCE ETHICON, Inc.
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...2 PDL BioPharma, Inc. (P...stablished the per share amount of the previously ...er share. The dividend will be paid on December 15... the December 1, 2009 record date. NASDAQ had prev...of the dividend at $1.67 per share of common stock...
(Date:12/2/2009)... 2 Clarient, Inc. (Nasda...urce for pathologists, oncologists and the pharmac...l Officer transition plan that calls for veteran f...its Senior Vice President and Chief Financial Offi...the current Senior Vice President and Chief Financ...
(Date:12/2/2009)... Dec. 2 Novartis announced today t...on on Tasigna® (nilotinib) 200 mg capsules in...he strength of the company,s hematology portfolio ...data, at the 51st American Society of Hematology (...company,s current therapies and investigational ag...
Breaking Medicine Technology:PDL BioPharma Announces December 15 Special Dividend Payment of $1.67 per Share 2PDL BioPharma Announces December 15 Special Dividend Payment of $1.67 per Share 3Clarient Announces CFO Transition Plan 2Clarient Announces CFO Transition Plan 3Clarient Announces CFO Transition Plan 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Walsh College and Ford Motor Company Fund and Community Services Team Up To Offer New Series of Take Charge Workshops for the Unemployed 12423 1Walsh College and Ford Motor Company Fund and Community Services Team Up To Offer New Series of Take Charge Workshops for the Unemployed 12423 2Walsh College and Ford Motor Company Fund and Community Services Team Up To Offer New Series of Take Charge Workshops for the Unemployed 12423 3Walsh College and Ford Motor Company Fund and Community Services Team Up To Offer New Series of Take Charge Workshops for the Unemployed 12423 4External beam partial breast irradiation most cost effective treatment 47644 1External beam partial breast irradiation most cost effective treatment 47644 2Researchers call for new space headache category following astronauts survey 47642 1Researchers call for new space headache category following astronauts survey 47642 2
... 20, 2007 /PRNewswire-USNewswire/ -- The,Christoph...,non-profit organization dedicated to finding cure...oving the lives of people living,with paralysis, t...Bush,s veto of the Stem Cell Research Enhancement ...ts in stem cell research with the,support and over...
...RE)--Jun 20, 2007 - Today, President Bush,Signed A...tment To,Research On Pluripotent Stem Cells. Scien...and skill to pursue the potential benefits,of plur...t have the,potential to develop into nearly all th...angering human life in the process. By,expanding s...
Other Medicine Technology:The Christopher and Dana Reeve Foundation Expresses Disappointment,Over President Bush's Veto of the Stem Cell Research Enhancement,Act 2The Christopher and Dana Reeve Foundation Expresses Disappointment,Over President Bush's Veto of the Stem Cell Research Enhancement,Act 3Fact Sheet: Advancing Stem Cell Research While Respecting Moral,Boundaries 2Fact Sheet: Advancing Stem Cell Research While Respecting Moral,Boundaries 3
(Date:12/2/2009)... Care Support of America,s model ...ced Illness Coordinated Care (AICC) , has been sho... life as well as improve the quality of life for s...ing mortality. These are the principal findings of...aged Care (November 2009). ,, Based on a r...
(Date:12/2/2009)...An avid tennis player and golfer, as well as baseb...creasingly frustrated over time as his eyesight di...er. Unable to return the tennis ball or see the pi...orneal transplant to restore his vision and eye co...d an alternative treatment. He received a gas perm...
(Date:12/2/2009)... been a top name in the medical supply industry si... professional staff, and a keen understanding of t...stablished itself as a provider of ground ambulanc...supplies distributor. The distinguished history of...ext phase with the redesign and launch of its webs...
(Date:12/2/2009)...Newswire/ -- The American Health Information Manag...nced Alan F. Dowling, PhD, will be the next chief ...management (HIM) leader. Dr. Dowling,s extensive ...ystems management, strategic expertise, governance...ship. He is scheduled to take office January 13, ...
(Date:12/2/2009)...swire-USNewswire/ -- At a recently concluded first...gates came together to outline the future of medic...ecessary thrust. Organized by the Medical Tourism ....com , the high-powered congregation of senior min...es and requests for assistance in medical tourism ...
Breaking Medicine News(10 mins):Health News:Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care 2Health News:Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care 3Health News:Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care 4Health News:Brandeis studies evaluate visionary approach to improving eyesight 2Health News:From A to B and Everything In-between; AB First Aid Launch New Web Storefront 2Health News:From A to B and Everything In-between; AB First Aid Launch New Web Storefront 3Health News:Dr. Alan F. Dowling Named AHIMA's Next Chief Executive Officer 2Health News:Ministerial Roundtable Discusses Future of Medical Tourism 2Health News:Ministerial Roundtable Discusses Future of Medical Tourism 3
...20 Lincare Holdings,Inc. (Nasdaq: LNCR ), a lead...py services delivered to patients in the home, tod...ine months ended September 30, 2008., For the qua...tes that the change in net revenues was comprised ...
...treatments less effective, more painful than singu...Day News) -- Laser therapies to remove unwanted ha...ately rather than in combination, according to an ...sing either long-pulsed 755-nanometer alexandrite ...
...n 330,000 lives were lost to HIV/AIDS in South Afr...ly antiretroviral (ARV) treatment program was not ...chool of Public Health (HSPH) in a study published...with HIV during that same period in the country be...
...ntists: Highlights of the Bush Presidency - A Plea...ey Among Health Advocates Reveals Chemical Exposur...t Impacts Public Health Presidential candidates a...on official representing EPA scientists, and many,...
...isoners who have hepatitis C with the standard the...e cost-effective, says a new study in the November...n Wiley & Sons on behalf of the American Associati...s incarcerate more than 2 million inmates each yea...
...e Duty Service Members to Be Served Beginning in ..., Pa., Oct. 20 United Concordia Companies,Inc. ha...ogram (ADDP),contract by the United States Departm...valued at approximately,$660 million, will begin A...
Other Medicine News:Health News:Lincare Holdings Inc. Announces Third Quarter and First Nine Months 2008 Financial Results 2Health News:Lincare Holdings Inc. Announces Third Quarter and First Nine Months 2008 Financial Results 3Health News:Lincare Holdings Inc. Announces Third Quarter and First Nine Months 2008 Financial Results 4Health News:Lincare Holdings Inc. Announces Third Quarter and First Nine Months 2008 Financial Results 5Health News:Lincare Holdings Inc. Announces Third Quarter and First Nine Months 2008 Financial Results 6Health News:Study Evaluates Laser Therapies for Hair Removal 2Health News:Researchers estimate lives lost due to delay in antiretroviral drug use for HIV/AIDS in South Africa 2Health News:Researchers estimate lives lost due to delay in antiretroviral drug use for HIV/AIDS in South Africa 3Health News:Researchers estimate lives lost due to delay in antiretroviral drug use for HIV/AIDS in South Africa 4Health News:Human Testing - Exposing Children to Chemicals 2Health News:Hepatitis C treatment is cost-effective for the US prison population 2Health News:National Dental Insurer United Concordia to Receive $660 Million Contract From U.S. Department of Defense 2
IEC CL31R Multispeed Centrifuge
IEC CL31 Multispeed Centrifuge
IEC CL30 Centrifuge
Automatic Blood Pressure Monitor
Medicine Products: